ENLV logo

ENLV
Enlivex Therapeutics Ltd

7,986
Mkt Cap
$193.7M
Volume
284,839.00
52W High
$2.10
52W Low
$0.66
PE Ratio
0.03
ENLV Fundamentals
Price
$0.816
Prev Close
$0.8198
Open
$0.84
50D MA
$0.9984
Beta
0.73
Avg. Volume
548,214.74
EPS (Annual)
$25.48
P/B
0.10
Rev/Employee
$0.00
$28.88
Loading...
Loading...
News
all
press releases
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
HC Wainwright Issues Pessimistic Outlook for ENLV Earnings
Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2026 earnings estimates for Enlivex Therapeutics in a research note issued to...
MarketBeat·23d ago
News Placeholder
Research Analysts Set Expectations for ENLV Q1 Earnings
Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Enlivex Therapeutics in a report released on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.02) per share...
MarketBeat·24d ago
News Placeholder
HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock
HC Wainwright boosted their target price on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday...
MarketBeat·25d ago
News Placeholder
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of Enlivex Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Enlivex Therapeutics Q4 Earnings Call Highlights
Enlivex Therapeutics (NASDAQ:ENLV) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what they described as a dual-engine strategy that combines clinical-stage...
MarketBeat·1mo ago
News Placeholder
Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS
Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $12.85 earnings per share for the quarter, beating analysts' consensus...
MarketBeat·1mo ago
News Placeholder
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Press Releases·1mo ago
News Placeholder
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Monday
Enlivex Therapeutics (NASDAQ:ENLV) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-enlivex-therapeutics-ltd-stock...
MarketBeat·1mo ago
News Placeholder
Enlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest ENLV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.